UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 193

Sortiert nach

Drotrecogin Alfa (Activated) in Adults with Septic Shock

The New England journal of medicine, 2012-05, Vol.366 (22), p.2055-2064

2012

Volltextzugriff (PDF)

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

Critical care medicine, 2008-01, Vol.36 (1), p.296-327

2008

Volltextzugriff (PDF)

Successful cardiopulmonary resuscitation after cardiac arrest as a sepsis-like syndrome

Circulation (New York, N.Y.), 2002-07, Vol.106 (5), p.562-568

2002

Volltextzugriff (PDF)

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

Intensive care medicine, 2008-01, Vol.34 (1), p.17-60

2008

Volltextzugriff (PDF)

Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial

The Lancet (British edition), 2006-07, Vol.368 (9533), p.379-385

2006

Volltextzugriff (PDF)

Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest

Journal of the American College of Cardiology, 2002-12, Vol.40 (12), p.2110-2116

2002

Volltextzugriff (PDF)

High-volume hemofiltration after out-of-hospital cardiac arrest : A randomized study

Journal of the American College of Cardiology, 2005-08, Vol.46 (3), p.432-437

2005

Volltextzugriff (PDF)

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment

Critical care medicine, 2005-10, Vol.33 (10), p.2266-2277

2005

Volltextzugriff (PDF)

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

The New England journal of medicine, 2001-03, Vol.344 (10), p.699-709

2001

Volltextzugriff (PDF)

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock

Intensive care medicine, 2008-11, Vol.34 (11), p.1935-1947

2008

Volltextzugriff (PDF)

Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study

Critical care medicine, 2005-05, Vol.33 (5), p.952-961

2005

Volltextzugriff (PDF)

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Critical care medicine, 2003-01, Vol.31 (1), p.12-19

2003

Volltextzugriff (PDF)

High Levels of Catalytic Antibodies Correlate with Favorable Outcome in Sepsis

Proceedings of the National Academy of Sciences - PNAS, 2005-03, Vol.102 (11), p.4109-4113

2005

Volltextzugriff (PDF)

One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic Fibrosis

American journal of respiratory and critical care medicine, 2005-01, Vol.171 (2), p.158-164

2005

Volltextzugriff (PDF)

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

Critical care (London, England), 2006-01, Vol.10 (3), p.R92-R92

2006

Volltextzugriff (PDF)

Underlying Disorders and Their Impact on the Host Response to Infection

Clinical infectious diseases, 2005-11, Vol.41 (Supplement-7), p.S481-S489

2005

Volltextzugriff (PDF)

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

Intensive care medicine, 2003-06, Vol.29 (6), p.894-903

2003

Volltextzugriff (PDF)

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Critical care medicine, 2004-02, Vol.32 (2), p.332-341

2004

Volltextzugriff (PDF)

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

Intensive care medicine, 2008-04, Vol.34 (4), p.783-785

2008

Volltextzugriff (PDF)

Unblinding plan of PROWESS-SHOCK trial

Intensive care medicine, 2011-08, Vol.37 (8), p.1384-1385

2011

Volltextzugriff (PDF)

LPS Challenge in D-galactosamine-Sensitized Mice Accounts for Caspase-dependent Fulminant Hepatitis, not for Septic Shock

American journal of respiratory and critical care medicine, 1999-04, Vol.159 (4), p.1308-1315

1999

Volltextzugriff (PDF)

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results

Critical care medicine, 2003-09, Vol.31 (9), p.2291-2301

2003

Volltextzugriff (PDF)

French intensivists do not apply American recommendations regarding decisions to forgo life-sustaining therapy

Critical care medicine, 2001-10, Vol.29 (10), p.1887-1892

2001

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(179)
Mit Volltextzugriff
(178)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(120)
Humans
(108)
General & Internal Medicine
(91)
Critical Care Medicine
(85)
Biological And Medical Sciences
(82)
Medical Sciences
(82)
Male
(57)
Female
(56)
Middle Aged
(56)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(55)
Intensive Care Medicine
(52)
Adult
(42)
Aged
(42)
Sepsis
(34)
Prospective Studies
(26)
Protein C - Therapeutic Use
(25)
Emergency And Intensive Care: Infection, Septic Shock
(23)
Recombinant Proteins - Therapeutic Use
(21)
Sepsis - Drug Therapy
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Drotrecogin Alfa (Activated) in Adults with Septic Shock

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

Successful cardiopulmonary resuscitation after cardiac arrest as a sepsis-like syndrome

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial

Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest

High-volume hemofiltration after out-of-hospital cardiac arrest : A randomized study

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock

Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Recherche et innovation en santé : comment optimiser l’interface entre les startups/industries et les établissements de santé académiques ou non ?

High Levels of Catalytic Antibodies Correlate with Favorable Outcome in Sepsis

One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic Fibrosis

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

Underlying Disorders and Their Impact on the Host Response to Infection

Using connected objects in clinical research

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

Unblinding plan of PROWESS-SHOCK trial

LPS Challenge in D-galactosamine-Sensitized Mice Accounts for Caspase-dependent Fulminant Hepatitis, not for Septic Shock

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results

French intensivists do not apply American recommendations regarding decisions to forgo life-sustaining therapy

Suchergebnisse filtern